沃华医药(002107) - 2023 Q3 - 季度财报

Financial Performance - The company's operating revenue for Q3 2023 was ¥224,083,321.85, a decrease of 10.10% compared to the same period last year[3] - The net profit attributable to shareholders for Q3 2023 was ¥20,197,283.93, down 12.33% year-on-year[3] - The net profit after deducting non-recurring gains and losses was ¥19,501,113.58, reflecting a 12.73% decline compared to the previous year[3] - Total operating revenue for the current period is 716,392,429.50, a decrease from 752,849,548.28 in the previous period, representing a decline of approximately 4.8%[17] - Operating profit for the current period is 47,714,006.59, down from 74,736,005.11, indicating a decline of approximately 36.2%[18] - Net profit for the current period is 46,438,288.71, compared to 63,423,848.29 in the previous period, a decrease of around 26.7%[19] - Basic and diluted earnings per share are both 0.10, down from 0.14 in the previous period, reflecting a decline of approximately 28.6%[19] Assets and Liabilities - The total assets at the end of Q3 2023 amounted to ¥1,119,024,036.45, representing a 1.73% increase from the end of the previous year[4] - The company's total liabilities decreased to CNY 285,735,266.39 from CNY 310,200,830.51, indicating a reduction in financial obligations[15] - The total equity attributable to shareholders increased to CNY 803,901,512.07 from CNY 746,500,239.28, reflecting a growth of approximately 7.5%[15] - The company's total liabilities decreased by 81.16% in contract liabilities, reflecting a reduction in advance payments received[7] - The company reported a significant increase of 199.30% in notes payable, attributed to an increase in bank acceptance bills issued during the reporting period[7] Cash Flow and Cash Management - The net cash flow from operating activities for the year-to-date period was ¥91,875,569.97, down 24.96% compared to the same period last year[8] - The company's cash and cash equivalents increased by 30.82% to ¥364,058,822.06 due to increased sales collections during the reporting period[7] - Cash flow from operating activities generated a net amount of 91,875,569.97, down from 122,443,327.65, a decrease of about 25%[22] - Cash and cash equivalents at the end of the period increased to 362,901,383.52 from 286,622,251.48, representing an increase of approximately 26.6%[23] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 40,947[10] Inventory and Receivables - Accounts receivable rose to CNY 117,953,452.76 from CNY 85,236,185.16, marking an increase of approximately 38.5%[13] - Inventory decreased to CNY 136,859,522.29 from CNY 146,034,842.03, a decline of about 6.5%[13] Expenses - Research and development expenses for the current period are 36,523,429.87, slightly down from 38,274,932.52, a decrease of about 4.6%[18] - Sales expenses increased to 396,000,546.49 from 393,799,547.98, reflecting a rise of approximately 0.6%[18] - Tax expenses decreased significantly to 1,773,603.76 from 10,119,935.70, a reduction of about 82.5%[18] Reporting and Compliance - The third quarter report of Shandong WoHua Pharmaceutical Technology Co., Ltd. has not been audited[24] - The company has implemented new accounting standards starting from 2023[24] - The financial statement items related to the first execution year have been adjusted accordingly[24] - The board of directors announced the third quarter report on October 26, 2023[24] - There are no specific performance summaries or user data provided in the document[24] - Future outlook and performance guidance details are not included in the report[24] - Information regarding new product and technology development is absent[24] - Market expansion and acquisition strategies are not mentioned[24] - Other new strategies are not discussed in the document[24] - The report does not provide any numerical data or percentage figures[24]